AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. (ATXI) Stock Price Target 2026

The average analyst price target for AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. is $56.25, 5765.5% above the current price. The one analyst covering it rates it Buy. The latest change came on Dec 11, 2023, when Maxim Group initiated coverage of AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. with a Buy rating and a $56.25 price target.

The Average Analyst Price Target for AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. is $56.25.

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$56.25Upside to Avg. PT+5765.5%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 11, 2023	Maxim Group	Jason McCarthy	Initiate	Buy	$56

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75

Maxim Group analyst Jason McCarthy initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $0.75.

Benzinga Newsdesk

PRO
Aegis Capital Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $32

Aegis Capital analyst David Bouchey initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $32.

Benzinga Newsdesk

HC Wainwright & Co. Maintains Buy on Avenue Therapeutics, Raises Price Target to $13

HC Wainwright & Co. maintains Avenue Therapeutics (NASDAQ:ATXI) with a Buy and raises the price target from $12 to $13.

Vick Meyer

Oppenheimer Initiates Coverage On Avenue Therapeutics with Outperform Rating, Announces $8 Price Target

Benzinga

H.C. Wainwright Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces $11 Price Target

Benzinga

15 Biggest Mid-Day Gainers For Tuesday

Benzinga